Content Spotlight
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
The acquisition will add Adaptate’s novel antibody-based delta T-cell engager platform to Takeda’s immune-oncology portfolio.
Takeda is set to acquire UK firm Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for the adaptation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.
In addition to gaining Adaptate’s antibody-based γδ T cell engager platform, Takeda will also obtain its preclinical candidate and discovery pipeline programs.
Image: Stock Photo Secrets
“Adaptate’s γδ T-cell engagers are engineered to specifically activate a γδ T cell-mediated immune response only at the tumor site while sparing damage to healthy cells,” a spokesperson for Takeda told BioProcess Insider.
“Adaptate has discovered a unique set of antibodies that selectively modulate γδ T-cell activity in the tumor microenvironment. The antibodies provide a precisely targeted signal to the immune system, triggering an immune response and direct γδ T-cell responses to specific tumor targets, thereby offering the opportunity for superior efficacy and safety compared to conventional immuno-oncology approaches in solid tumors.”
Takeda said Adaptate’s platform, combined with its intent to acquire GammaDelta Therapeutics’ cell therapy-based platform announced in October 2021, provides the firm with “with the opportunity to more fully leverage γδ T-cell, anti-tumor biology to potentially develop uniquely effective cancer treatments for solid tumors and hematologic malignancies.”
Adaptate was formed in 2019 as a spin-out company from GammaDelta with funding from Takeda and Abingworth LLP. Takeda received the exclusive right to buy Adaptate for an undisclosed pre-negotiated upfront payment.
The deal is anticipated to be completed the first quarter of 2022 and Adaptate’s employees will be “integrated into Takeda’s R&D organization,” but “is unable to provide final guidance on individual employment plans until after the acquisition is finalized.”
You May Also Like